Transparency notification received from SFPI/FPIM

Bone Therapeutics SA


Article 14 of the law of May 2, 2007 on the publication of major shareholdings

Mont-Saint-GuibertBelgium, 11 October 20227:00 am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other pathologies, announces today that it has received a transparency notification from the SFPI (Société Fédérale de Participation et d’Investissement)/ FPIM (Federale Participatien en Investeringsmaatschappij) dated October 04, 2022. The transparency notification indicates that the participations held by the SFPI/FPIM have passively crossed the 5% threshold.

The notification dated October 04, 2022 contains the following information:

  • Reason for notification:

  • Notification by: A parent company or a controlling person

  • Persons subject to the declaration obligation: SFPI/FPIM – Belgian State

  • Transaction date: September 29 2022

  • Threshold crossed: 5%

  • Denominator: 23,835,971

Right to vote

Previous notification

After the deal

Voting rights holders

# of right to vote

# of right to vote

% of right to vote

belgian state





416 406



Total voting rights

416 406



The notification can be viewed on the Bone Therapeutics website, under the heading “Information to shareholders”.

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company focused on developing innovative products to address significant unmet needs in orthopedics and other diseases. Currently, Bone Therapeutics is specifically focused on the development of its most advanced clinical asset, the allogeneic cell therapy platform, ALLOB.

Bone Therapeutics’ core technology is based on its state-of-the-art allogeneic cell and gene therapy platform with differentiated mesenchymal stromal cells (MSCs) from bone marrow that can be stored at the point of use in the hospital. Its lead investigational drug, ALLOB, represents a proprietary and unique approach to bone regeneration that transforms undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced through Bone Therapeutics’ scalable manufacturing process. Following the approval of the CTA by the regulatory authorities in Europe, the Company has initiated the recruitment of patients for the Phase IIb clinical trial with ALLOB in patients suffering from difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by an extensive IP (Intellectual Property) portfolio spanning ten patent families as well as know-how. The Company is based in Louvain-la-new Mont-Saint-Guibert Science Park, Belgium. Further information is available at

For more information, please contact:

Bone Therapeutics SA
Miguel Forte, MD, PhD, President and CEO
Tel: +32 (0)71 12 10 00
[email protected]

For Belgian media and investor enquiries:
Bert Bouserie
Tel: +32 (0)488 40 44 77
[email protected]

International Media Requests:
Image box communication
Neil Hunter/Michelle Boxall
Tel: +44 (0)20 8943 4685
[email protected] / [email protected]

For French media and investor enquiries:
NewCap Investor Financial Relations & Communication
Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouille
Tel: +33 (0)1 44 71 94 94
[email protected]

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, if applicable, the directors of the Company regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Accordingly, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release. Consequently any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based. Neither the Company, nor its advisers or representatives, nor any of its subsidiaries or the officers or employees of such persons warrant that the assumptions underlying these forward-looking statements are free from error and accept no responsibility for the future accuracy of forward-looking statements. statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Comments are closed.